MedTrace Logo

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT03257033 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2025-11-14

No results posted yet for this study

Summary

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Conditions

Interventions

DRUG

Gemcitabine

Chemotherapy

DRUG

nab-paclitaxel

Chemotherapy

DEVICE

RenovoCath

Intra-arterial catheter

Sponsors & Collaborators

  • RenovoRx

    lead INDUSTRY

Principal Investigators

  • Michael J Pishvaian · Johns Hopkins Kimmel Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2026-06-30
Completion
2026-09-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03257033 on ClinicalTrials.gov